GMTX vs. ABCL, LGND, AKRO, VRNA, PCRX, XNCR, GYRE, DCPH, IRWD, and DAWN
Should you be buying Gemini Therapeutics stock or one of its competitors? The main competitors of Gemini Therapeutics include AbCellera Biologics (ABCL), Ligand Pharmaceuticals (LGND), Akero Therapeutics (AKRO), Verona Pharma (VRNA), Pacira BioSciences (PCRX), Xencor (XNCR), Gyre Therapeutics (GYRE), Deciphera Pharmaceuticals (DCPH), Ironwood Pharmaceuticals (IRWD), and Day One Biopharmaceuticals (DAWN). These companies are all part of the "pharmaceutical preparations" industry.
Gemini Therapeutics (NASDAQ:GMTX) and AbCellera Biologics (NASDAQ:ABCL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, community ranking, dividends and analyst recommendations.
In the previous week, AbCellera Biologics had 2 more articles in the media than Gemini Therapeutics. MarketBeat recorded 3 mentions for AbCellera Biologics and 1 mentions for Gemini Therapeutics. AbCellera Biologics' average media sentiment score of 1.05 beat Gemini Therapeutics' score of 0.05 indicating that AbCellera Biologics is being referred to more favorably in the news media.
75.4% of Gemini Therapeutics shares are held by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are held by institutional investors. 12.9% of Gemini Therapeutics shares are held by company insiders. Comparatively, 32.5% of AbCellera Biologics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
AbCellera Biologics has a consensus price target of $15.86, indicating a potential upside of 279.36%. Given AbCellera Biologics' higher probable upside, analysts plainly believe AbCellera Biologics is more favorable than Gemini Therapeutics.
Gemini Therapeutics has a net margin of 0.00% compared to AbCellera Biologics' net margin of -384.99%. AbCellera Biologics' return on equity of -12.36% beat Gemini Therapeutics' return on equity.
AbCellera Biologics received 31 more outperform votes than Gemini Therapeutics when rated by MarketBeat users. Likewise, 76.92% of users gave AbCellera Biologics an outperform vote while only 63.33% of users gave Gemini Therapeutics an outperform vote.
Gemini Therapeutics has a beta of -0.12, meaning that its stock price is 112% less volatile than the S&P 500. Comparatively, AbCellera Biologics has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500.
Gemini Therapeutics has higher earnings, but lower revenue than AbCellera Biologics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.
Summary
AbCellera Biologics beats Gemini Therapeutics on 13 of the 16 factors compared between the two stocks.
Get Gemini Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GMTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gemini Therapeutics Competitors List
Related Companies and Tools
